The role of cortisol and steroid hormone metabolism for sarcopenia in chronic kidney disease; a cross-sectional study

niversity of Birmingham0 个研究点目标入组 50 人开始时间: 2022年4月11日最近更新: 2022年5月30日

适应症

试验速览

暂无简介。

•1. Men and women
•2. Age 60-80 years
•3. For CKD group (recruitment target 30): chronic kidney disease stage IV or V (eGFR less than 30ml/min for more than 3 months)
•4. For control group (recruitment target 20): no history of kidney disease or other major chronic illness
•5. Willing and able to provide informed consent

•1. Receive steroid medications or hormone replacement therapy other than thyroxine for well-controlled hypothyroidism
•2. Have a primary neurological or muscle disease that impairs muscle function
•3. Be at extremes of body weight (BMI <18 or >35kg/m²)
•4. Have a diagnosis of cancer in the past 5 years (except non-melanoma skin cancer)
•5. Suffered an acute illness requiring hospital admission within the past month
•6. Have a bleeding predisposition or receive anticoagulation (except aspirin that can be suspended for 3 days without significant clinical risk)
•7. Be enrolled in another clinical trial with a treatment intervention within past four months

发起方